Clinical Trials Logo

Myelodysplasia clinical trials

View clinical trials related to Myelodysplasia.

Filter by:

NCT ID: NCT03674411 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Start date: January 2, 2019
Phase: Phase 2
Study type: Interventional

This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will receive a uniform myeloablative conditioning and post-transplant immunoprophylaxis.

NCT ID: NCT03613727 Completed - Myelodysplasia Clinical Trials

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.

NCT ID: NCT03480360 Active, not recruiting - Lymphoma Clinical Trials

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Start date: March 28, 2018
Phase: Phase 3
Study type: Interventional

The standard Johns Hopkins' regimen will be used in study subjects, with the use of donor peripheral blood stem cells, rather than marrow. Clinical outcomes will be defined while focusing efforts on immune reconstitution focusing on immune checkpoint regulators after a related haploidentical stem cell transplant.

NCT ID: NCT03431090 Active, not recruiting - Clinical trials for Hematologic Malignancy

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

Start date: March 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.

NCT ID: NCT03387475 Recruiting - Myelodysplasia Clinical Trials

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

LODEFI
Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

Patients with low-risk MDS verifying the eligibility criteria may be included in the study.

NCT ID: NCT03314974 Recruiting - Multiple Myeloma Clinical Trials

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Start date: March 30, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

NCT ID: NCT02765997 Withdrawn - Clinical trials for Acute Myeloid Leukemia

StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

Start date: April 2017
Phase: Phase 2
Study type: Interventional

This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a myeloablative CY/FLU/TBI conditioning. A 2:1 randomization will be employed with a higher chance of being assigned to the experimental arm.

NCT ID: NCT02345850 Completed - Acute Leukemia Clinical Trials

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Start date: August 2015
Phase: Phase 3
Study type: Interventional

The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation.

NCT ID: NCT02338479 Active, not recruiting - Clinical trials for Acute Myelogenous Leukemia

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Start date: March 2015
Phase:
Study type: Observational

This is a prospective non-therapeutic study, assessing the long-term toxicity of pediatric HCT for hematologic malignancies. This study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC), the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Marrow Transplant Program (NMDP) and the Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI-BMT) of the CIBMTR. The study will enroll pediatric patients who undergo myeloablative HCT for hematologic malignancies at PBMTC sites.

NCT ID: NCT02323867 Recruiting - Lymphoma Clinical Trials

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

AB-CliniMACs
Start date: October 2014
Phase: Phase 2
Study type: Interventional

This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.